About Sangamo

Sangamo Therapeutics is a biotechnology company specializing in genomic engineering and gene therapy. They focus on developing transformative therapies for devastating diseases, primarily hemoglobinopathies (such as beta-thalassemia) and monogenic genetic disorders. Their portfolio includes Zynteglo™ (autologous ex vivo-transduced CAR T cells), which is the first approved gene therapy in Europe, and SB-525, a potential treatment for hemophilia A. Sangamo's innovative approach utilizes zinc finger nucleases to modify DNA sequences, thereby correcting genetic defects at their source.